Downloads: 0 | Views: 141
Comparative Studies | Anaesthesiology | India | Volume 11 Issue 11, November 2022
Dexmedetomidine as an Adjuvant to Levobupivacaine in Paravertebral Block for Postoperative Analgesia after Breast Cancer Surgery
Dr. Mudhanuru Bhargava Mallesh Yadav | Dr. G. Vijaya Lakshmi [5] | Dr. Anil Kumari [3] | Dr. Joga Aparna [4]
Abstract: Introduction: Currently regional technique-thoracic paravertebral block for postoperative analgesia after breast surgery is gaining popularity. Aim of the study is to find out the safety and the analgesic efficacy of 1 ?g/kg dexmedetomidine when added to levobupivacaine 0.25% in paravertebral blocks (PVB) in patients undergoing breast cancer surgery. Methods: Sixty American Society of Anaesthesiologists physical statusI/II patients posted for breast cancer surgery were randomly assigned into two groups of 30 each. Group L received thoracic PVB with 20 mL of levobupivacaine 0.25%. Group LD received thoracic PVB with 20 mL of levobupivacaine 0.25% + 1 ?g/kg dexmedetomidine. Time of first analgesics request, total analgesic consumption, VAS score, hemodynamic, sedation score and side effects in the first 24 hours were recorded. Results: The time of the first rescue analgesic requirement was significantly prolonged in the group LD (8.15 ? 2.21 hours) in comparison to group L (6.34 ? 2.83 hours). The mean total consumption of intravenous tramadol as rescue analgesia in the post-anaesthesia care unit in the first 24 hours postoperatively was significantly decreased in group Levobupivacaine + Dexmeditomidine compared to group Levobupivacaine. Conclusion: The addition of dexmedetomidine 1 ?g/kg to levobupivacaine 0.25% in PVB in patients undergoing breast cancer surgery improves the quality and the duration of analgesia postoperatively.
Keywords: Dexmedetomidine, Levobupivacaine, Paravertebral Block, Postoperative Analgesia, Breast Cancer
Edition: Volume 11 Issue 11, November 2022,
Pages: 414 - 416